What is the recommended hormonal therapy regimen for a menopausal woman with moderate to severe vasomotor symptoms, including indications, contraindications, dosing, uterine status considerations, and non‑hormonal alternatives?

Hormonal Therapy for Menopause

For menopausal women under age 60 or within 10 years of menopause onset with moderate to severe vasomotor symptoms, initiate estrogen therapy alone if the uterus is absent, or estrogen plus progestogen if the uterus is present—this remains the most effective treatment, reducing vasomotor symptoms by approximately 75%. 1, 2

Indications and Patient Selection

Hormonal therapy is indicated for:

• Moderate to severe vasomotor symptoms (hot flashes, night sweats) that interfere with quality of life
• Women under age 60 or within 10 years of menopause onset
• Absence of contraindications (see below)

The "timing hypothesis" is critical here: age and time since menopause are the strongest predictors of benefit-risk ratio. Women meeting these criteria have favorable outcomes for all-cause mortality, myocardial infarction, and overall benefit 1, 3.

Contraindications

Absolute contraindications:

• History of breast cancer
• Active cardiovascular disease or high CVD risk
• History of venous thromboembolism or stroke
• Active liver disease
• Unexplained vaginal bleeding
• Known or suspected pregnancy

For women at high cardiovascular risk, use nonhormonal therapies instead 1. For women with moderate cardiovascular risk, transdermal estradiol is preferred over oral formulations 1, 4.

Regimen Selection Based on Uterine Status

Women WITHOUT a Uterus

• Estrogen therapy (ET) alone
• No progestogen needed (no endometrial protection required)
• Options include conjugated equine estrogens or transdermal estradiol

Women WITH a Uterus

• Estrogen plus progestogen therapy (EPT) is mandatory to prevent endometrial hyperplasia and cancer 1
• Preferred regimen for moderate CVD risk: Transdermal estradiol combined with micronized progesterone (fewer adverse metabolic effects) 1
• Alternative: Conjugated equine estrogens/bazedoxifene combination—this option does not increase breast cancer risk (0.25%/year vs 0.23%/year with placebo) 2, 1

Critical pitfall: Never give unopposed estrogen to women with an intact uterus—this dramatically increases endometrial cancer risk.

Dosing and Route of Administration

Use FDA-approved preparations only—avoid custom-compounded "bioidentical" hormones 1.

Route considerations:

• Transdermal estradiol has lower risk of venous thromboembolism and stroke compared to oral formulations 1, 4
• Oral and transdermal estrogen have similar efficacy for vasomotor symptoms (75% reduction) 2
• For women with moderate CVD risk, metabolic syndrome, or elevated VTE risk, prioritize transdermal delivery 1, 5

Start with the lowest effective dose and use shared decision-making to determine formulation, dose, and route 1.

Monitoring and Duration

Annual reassessment is mandatory 1. At each visit:

• Evaluate persistent need for therapy based on symptom control
• Reassess cardiovascular and breast cancer risk
• Target the shortest duration consistent with treatment goals

For persistent unscheduled bleeding: Immediately evaluate to rule out endometrial hyperplasia or cancer 1.

Breast cancer screening: Inform patients that EPT (not ET alone) increases breast cancer risk by approximately 1 excess event per 1,000 person-years 2. Emphasize adherence to age-appropriate screening 1.

Special population—Primary ovarian insufficiency/premature menopause: Continue MHT until the anticipated age of natural menopause (~51 years), then reassess 1.

Nonhormonal Alternatives

For women with contraindications to hormones or who decline hormonal therapy, effective nonhormonal options reduce vasomotor symptoms by 40-65% 2:

FDA-approved:

• Paroxetine (low-dose, 7.5 mg)—the only FDA-approved nonhormonal medication specifically for vasomotor symptoms
• SSRIs/SNRIs: Citalopram, escitalopram, venlafaxine, desvenlafaxine 2
• Gabapentin 2
• Neurokinin receptor antagonists (newer option with improved sleep and quality of life benefits) 6

Lifestyle modifications for mild symptoms:

• Lower ambient temperature
• Layer clothing
• Avoid alcohol and spicy foods
• Weight reduction if obese
• Stress management 1

Key Clinical Pearls

The "10-year/age 60 window" is the cornerstone of safe prescribing. Beyond this window, absolute risks of coronary heart disease, stroke, VTE, and dementia increase substantially, making the benefit-risk ratio less favorable 1, 3.

Route matters for safety: Transdermal estrogen consistently shows lower thrombotic risk than oral formulations across multiple studies 5, 4.

Progestogen selection matters: Micronized progesterone has fewer adverse metabolic effects than synthetic progestogens like medroxyprogesterone acetate 1.

Discontinuation approach: Use shared decision-making to choose between gradual taper versus abrupt discontinuation based on patient preference 1.